Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Immune-related adverse events
•
Neurology
•
Neuromuscular
How do you manage immunotherapy-induced myasthenia gravis?
Answer from: at Academic Institution
My go-to algorithm is well-represented in the paper by Dr. @Adeel Zubair et al. Zubair et al., PMID 36439604
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
NCCN "Management of Immunotherapy-Related Toxicities" has a useful 'cheat sheet' as a quick reference for the overnight call.
Sign in or Register to read more
19074
19390
Related Questions
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
Would you recommend muscle or nerve biopsy in a patient with amyoplasia congenita?
Would you consider adding gabapentin off label for use in the treatment of glioblastoma at this time?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do you counsel patients on the benefits of immunotherapy for anti-MAG neuropathy?
How do you counsel patients with dermatomyositis on sun protection?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
To what extent do you incorporate electrodiagnostic testing and ultrasonography in your clinical practice for evaluating suspected cases of meralgia paresthetica?
Are you offering Lutathera for multiple recurrent meningiomas?
How would one approach treating a patient with primary immunodeficiency on IVIG treatment who develops myasthenia gravis?